Gemoscan Canada Licenses Its Evolutionary HEMOCODE(TM) Food Intolerance System for Israel

Gemoscan Canada, Inc. (TSX VENTURE:GES)(MUN:1GE) ("Gemoscan") announced today
that it has entered into an agreement with Haemodek Limited ("Haemodek"), an
Israeli corporation, for the exclusive right to use and commercialize its
HEMOCODE(TM) FOOD INTOLERANCE SYSTEM, in Israel. The agreement also provides
Haemodek with a first right of refusal and opportunity to commercialize
HEMOCODE(TM), in Greece, Cyprus and Turkey. The HEMOCODE(TM) System is based on
Gemoscan's proprietary technology and processes, which are considered to be the
industry's most comprehensive method for managing food sensitivities. 


The agreement has an initial term of five years, provides for an initial
one-time license fee and monthly-earned royalty payments to Gemoscan by
Haemodek. 


"We are very excited by the prospect of commercializing what we believe is the
best and most comprehensive food intolerance management program, for Israel.
HEMOCODE(TM) will be quickly welcomed by high tech, health conscious Israeli
consumers as the recognized leader in personal wellness solutions," said Berl
Bessin, President of Haemodek.


According to an April 2012 report by Global Industry Analysts, Inc. the global
food allergy and intolerance products market is expected to surpass $26.5
billion by 2017. Already used successfully by thousands of Canadians, Gemoscan's
food intolerance management solutions employ patented technology to simplify the
recognition and management of food sensitivities. Using just a few drops of
blood and factoring an individual's medical history Gemoscan's systems manage
immune-based reactions to common foods and additives. 


"It is extremely gratifying to our team that Haemodek is taking the lead in
commercializing our food intolerance system technology for consumers in a
high-growth, technologically advanced, international market such as Israel where
increasingly, consumers are becoming more interested in their health and
wellness. Gemoscan's food intolerance system programs are unparalleled in the
market and can help consumers take control of their lifestyle issues by
identifying complementary natural solutions for well-being," said Brian Kalish,
Gemoscan President and Chief Executive Officer. "We intend to continue to
leverage our first to market, direct to consumer, industry leading position
through regular improvement of our cutting edge platforms. With our first mover
advantage and game changing solutions in commercializing food sensitivity
management programs for consumption at retail, we stand to be a considerable
force in the ever emerging global market for food intolerance products and
services."


ABOUT GEMOSCAN CANADA, INC. 

Gemoscan is an industry leader in food intolerance management and maintains a
first-to-market position with Canada wide distribution through select retail
partners. Founded in 2003, using its proprietary patented technology, Gemoscan
develops, owns and markets comprehensive food sensitivity and dietary management
solutions for consumers, including the HEMOCODE(TM) Food Intolerance System, a
personalized naturopathic nutritional program that promotes well-being. Gemoscan
is the first and only provider to commercialize a food intolerance management
solution directly to consumers in partnership with retailers, and today offers
the most comprehensive services available.


Gemoscan Canada, Inc. trades its shares on the Toronto Venture Exchange (TSX-V)
under the symbol GES and is quoted on the Munich, Frankfurt and Stuttgart Stock
Exchanges under the symbol 1GE.


ABOUT THE HEMOCODE(TM) FOOD INTOLERANCE SYSTEM 

The HEMOCODE(TM) Food Intolerance System is a personalized naturopathic
nutritional program that promotes dietary well-being. It uses patented
technology and services to provide consultation and recommendations to simplify
the management of food sensitivities. The HEMOCODE(TM) Food Intolerance System
is one of a growing number of wellness services and products offered by
pharmacies as complementary medical choices. Complementary medicine is an
adjunct to conventional medical practice, incorporating alternative modalities
and therapies with a focus on lifestyle and wellness. A statistically
significant base of practitioners and those using HEMOCODE(TM) report improved
dietary wellness and satisfaction.


ABOUT HAEMODEK LIMITED 

Haemodek Limited was founded by successful international entrepreneurs, through
a network of private investment funds, initiated to specifically take advantage
of rapidly emerging trends in the biotechnology, health and wellness markets.
Haemodek is the exclusive licensee of the HEMOCODE(TM) Food Intolerance System
in Israel.


Forward-Looking Information 

This news release contains certain "forward-looking information". All
statements, other than statements of historical fact that address activities,
events or developments that Gemoscan believes, expects or anticipates will or
may occur in the future. These forward-looking statements reflect the current
expectations or beliefs of Gemoscan based on information currently available to
Gemoscan. Forward-looking statements are subject to a number of significant
risks and uncertainties and other factors that may cause the actual results of
Gemoscan to differ materially from those discussed in the forward-looking
statements, and even if such actual results are realized or substantially
realized, there can be no assurance that they will have the expected
consequences to, or effects on Gemoscan. Any forward-looking statement speaks
only as of the date on which it is made and, except as may be required by
applicable securities laws, Gemoscan disclaims any intent or obligation to
update any forward-looking statement, whether as a result of new information,
future events or results or otherwise. Although Gemoscan believes that the
assumptions inherent in the forward-looking statements are reasonable,
forward-looking statements are not guarantees of future performance and
accordingly undue reliance should not be put on such statements due to the
inherent uncertainty therein.
Gemoscan Canada, Inc. (TSXV:GES)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024